Home › Cancro al seno › Minnesota › Rochester
Studi clinici su Cancro al seno a Rochester, MN
42 studi su Cancro al seno cercano partecipanti presso sedi a Rochester e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
In reclutamentoFase 2Volontari sani benvenuti
- Mayo Clinic in Rochester, Rochester
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
In reclutamentoFase 2
- Mayo Clinic, Rochester
PRE-ISPY Phase I/II Oncology Platform Program
In reclutamentoFase 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
In reclutamento
- Mayo Clinic, Rochester
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
In reclutamentoFase 2
- Mayo Clinic Cancer Center, Rochester
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
In reclutamento
- Mayo Clinic, Rochester
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
In reclutamentoFase 3
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
In reclutamentoFase 2
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
In reclutamentoFase 1
- Mayo Clinic - Rochester, Rochester
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
In reclutamentoFase 2
- Mayo Clinic, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
In reclutamentoFase 1/2
- Mayo Rochester, Rochester
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
In reclutamentoFase 3
- Mayo Clinic, Rochester
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
In reclutamentoFase 1
- Mayo Clinic, Rochester
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
In reclutamentoFase 1/2
- Mayo Clinic, Rochester
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
In reclutamentoFase 3
- Mayo Clinic in Rochester, Rochester
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
In reclutamentoFase 3
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Rochester
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
In reclutamentoFase 1
- Mayo Clinic, Rochester
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Mayo Clinic in Rochester, Rochester
A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
In reclutamento
- Mayo Clinic in Rochester, Rochester
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
In reclutamentoFase 3
- Mayo Clinic in Rochester, Rochester
E-Mindfulness Approaches for Living After Breast Cancer
In reclutamentoFase 3
- Mayo Clinic in Rochester, Rochester
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
In reclutamentoFase 1
- Mayo Clinic in Rochester, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
In reclutamentoFase 1
- Mayo Clinic Rochester, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic - Rochester, Rochester
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
In reclutamentoFase 3
- Mayo Clinic - Rochester, Rochester
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
In reclutamentoFase 1 iniziale
- Mayo Clinic in Rochester, Rochester
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
In reclutamentoFase 1
- Mayo Clinic Rochester, Rochester
3D Ultrasound Breast Imaging
In reclutamento
- Mayo Clinic in Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
In reclutamento
- Mayo Clinic, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
In reclutamentoFase 2
- Mayo Clinic, Rochester
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
In reclutamentoFase 3
- Mayo Clinic in Rochester, Rochester
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
In reclutamentoFase 1/2
- Mayo Clinic, Rochester
Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
In reclutamentoStudio osservazionale
- Mayo Clinic in Rochester, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
In reclutamentoFase 1/2
- Mayo Clinic, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
In reclutamentoStudio osservazionale
- Mayo Clinic, Rochester
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
In reclutamentoStudio osservazionale
- Mayo Clinic, Rochester
Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
In reclutamentoStudio osservazionale
- Mayo Clinic in Rochester, Rochester
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
In reclutamentoStudio osservazionale
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Mayo Clinic, Rochester
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
In reclutamento
- Mayo Clinic in Rochester, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #14, Rochester
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
In reclutamentoFase 1
- Biotheryx Investigative Site, Rochester
Studi su Cancro al seno in altre città
- New York City, NY134 studi
- Houston, TX126 studi
- Boston, MA111 studi
- Nashville, TN80 studi
- Los Angeles, CA72 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Durham, NC63 studi
- Queens, NY63 studi
- Chicago, IL58 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Altri studi a Rochester
- Cancro del polmone non a piccole cellule37 studi
- Cancro metastatico31 studi
- Cancro (tutti i tipi)30 studi
- Cancro colorettale29 studi
- Cancro ovarico29 studi
- Mieloma multiplo24 studi
- Cancro alla prostata22 studi
- Insufficienza cardiaca22 studi
- Cancro pancreatico22 studi
- Cancro ai polmoni20 studi
- Cancro dell'endometrio20 studi
- Leucemia linfatica cronica19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.